Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
1. To evaluate the safety of orally administered Lactobacillus plantarum strains 299 and
299v, a probiotic, in patients undergoing allogeneic myeloablative HSCT, as measured by
incidence of Lactobacillus plantarum bacteremia.
Secondary Objectives:
1. To investigate the feasibility of administering Lactobacillus plantarum 299 and 299v to
children and adolescents undergoing HSCT.
2. To describe the overall incidence of bacteremia in HSCT patients who have been
administered Lactobacillus plantarum.
3. To describe the overall incidence of acute graft versus host disease (GVHD) in HSCT
patients who have been administered Lactobacillus plantarum.
Phase:
Phase 1
Details
Lead Sponsor:
Columbia University Monica Bhatia
Collaborators:
Johns Hopkins All Children's Hospital Nemours Children's Clinic